Skip to main content
Log in

Angelman Syndrome

Etiology, Clinical Features, Diagnosis, and Management of Symptoms

  • Therapy In Practice
  • Published:
Pediatric Drugs Aims and scope Submit manuscript

Abstract

It is estimated that Angelman syndrome (AS) accounts for up to 6% of all children presenting with severe mental retardation and epilepsy. The main clinical features of AS may not be apparent early in life. Clinical findings present in all patients include developmental delay, which becomes apparent by 6–12 months of age, severely impaired expressive language, ataxic gait, tremulousness of limbs, and a typical behavioral profile, including a happy demeanor, hypermotoric behavior, and low attention span. Seizures, abnormal electroencephalography, microcephaly, and scoliosis are observed in >80% of patients.

Approximately 70% of patients show a deletion involving the maternally inherited chromosome 15q11-q13, encompassing a cluster of γ-aminobutyric acid receptor subunit genes, 3% show chromosome 15 paternal uniparental disomy (UPD), 1% harbor a mutation in the imprinting center (a transcriptional regulatory element), and 6% harbor intragenic mutations of the ubiquitin-protein ligase E3A (UBE3A) gene. Twenty percent of patients have no detectable genetic abnormality. Rare cases of familial recurrence of AS show either imprinting center (IC) or UBE3A mutations. Approximately 75% of cases are detected through the methylation test, which allows the detection of AS due to deletions, UPD and IC mutations. Mutation analysis of the UBE3A gene should be performed when the methylation test is negative.

Individuals with chromosome 15q11-q13 deletions have a more severe clinical picture and are more prone to develop severe epilepsy. Epilepsy has typical features, including absence and myoclonic seizures, and insidious episodes of nonconvulsive or subtle myoclonic status which are easily overlooked as children appear apathetic or in a state of neurologic regression. Tremulousness, present in all patients even when seizures are well controlled or absent, is related to distal cortical myoclonus. Valproic acid (sodium valproate), benzodiazepines, and ethosuximide, in various combinations, are quite effective in treating the typical seizure types. Piracetam may help in reducing distal myoclonus. Carbamazepine and vigabatrin may seriously aggravate absence and myoclonic seizures and should be avoided.

Cognitive, language, and orthopedic problems must be addressed with vigorous rehabilitation programs, including early physical therapy, which may help to develop communicative skills and prevent severe scoliosis and subsequent immobility. Where these treatment strategies are applied, individuals with AS may reach an appreciable level of integration, self care, and have a normal life span.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Table I
Table II
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Angelman H. “Puppet children”: a report on three cases. Dev Med Child Neurol 1965; 7: 681–8

    Article  Google Scholar 

  2. Bower BD, Jeavons PM. The “happy puppet” syndrome. Arch Dis Child 1967; 42: 298–301

    Article  PubMed  CAS  Google Scholar 

  3. Williams CA, Frias JL. The Angelman (‘happy puppet’) syndrome. Am J Med Genet 1982; 11: 453–60

    Article  PubMed  CAS  Google Scholar 

  4. Berg JM, Pakula Z. Angelman’s (“happy puppet”) syndrome. Am J Dis Child 1972; 123: 72–7

    PubMed  CAS  Google Scholar 

  5. Laan LAEM, Haeringen A, Brouwer OF. Angelman syndrome: a review of clinical and genetic aspects. Clin Neurol Neurosurg 1999; 101: 161–70

    Article  PubMed  CAS  Google Scholar 

  6. Clayton-Smith J, Pembrey ME. Angelman syndrome. J Med Genet 1992; 29: 412–5

    Article  PubMed  CAS  Google Scholar 

  7. Steffenburg S, Gillberg CL, Steffenburg U, et al. Autism in Angelman syndrome: a population-based study. Pediatr Neurol 1996; 14: 131–6

    Article  PubMed  CAS  Google Scholar 

  8. Kyllerman M. On the prevalence of Angelman syndrome [letter]. Am J Med Genet 1995; 59: 405

    Article  PubMed  CAS  Google Scholar 

  9. Godfrey M. Happy puppet syndrome. Nurs Mirror Midwives J 1976; 143: 45–6

    PubMed  CAS  Google Scholar 

  10. Jiang Y, Lev-Lehman E, Bressler J, et al. Genetics of Angelman syndrome. Am J Hum Genet 1999; 65: 1–6

    Article  PubMed  CAS  Google Scholar 

  11. Reik J, Walter J. Genomic imprinting: parental influence on the genome. Nat Rev Genet 2001; 2: 21–32

    Article  PubMed  CAS  Google Scholar 

  12. Albrecht U, Sutcliffe JS, Cattanach BM, et al. Imprinted expression of the murine Angelman syndrome gene, Ube3a, in hippocampal and Purkinje neurons. Nat Genet 1997; 17: 75–8

    Article  PubMed  CAS  Google Scholar 

  13. Angelman syndrome: Online Mendelian Inheritance in Man [online]. Available from URL: http://www3.ncbi.nlm.nih.gov/htbin-post/Omim/dispmim?.105830 [Accessed 2003 Apr 9]

  14. Watson P, Black G, Ramsden S, et al. Angelman syndrome phenotype associated with mutations in MECP2, a gene encoding a methyl CpG binding protein. J Med Genet 2001; 38: 224–8

    Article  PubMed  CAS  Google Scholar 

  15. William CA, Angelman H, Cleyton-Smith J, et al. Angelman syndrome: consensus for diagnostic criteria. Am J Med Genet 1995; 56: 237–8

    Article  Google Scholar 

  16. Dorries A, Spohr L, Kunze J. Angelman (‘happy puppet’) syndrome: seven new cases documented by cerebral computed tomography: review of the literature. Eur J Pediatr 1988; 148: 270–3

    Article  PubMed  CAS  Google Scholar 

  17. Magenis RE, Toth-Fejel S, Allen LJ, et al. Comparison of the 15q deletions in Prader-Willi and Angelman syndrome: specific regions, extent of deletions, parental origin and clinical consequences. Am J Med Genet 1990; 35: 333–49

    Article  PubMed  CAS  Google Scholar 

  18. Fryburg JS, Breg WR, Lindgren V. Diagnosis of Angelman syndrome in infants. Am J Med Genet 1991; 38: 58–64

    Article  PubMed  CAS  Google Scholar 

  19. Zori RT, Hendrickson I, Woolven S, et al. Angelman syndrome: clinical profile. J Child Neurol 1992; 7: 279–80

    Article  Google Scholar 

  20. Viani F, Romeo A, Viri M, et al. Seizure and EEG patterns in Angelman’s syndrome. J Child Neurol 1995; 10: 467–71

    Article  PubMed  CAS  Google Scholar 

  21. Matsumoto A, Kumagai T, Miura K, et al. Epilepsy in Angelman syndrome associated with chromosome 15q deletion. Epilepsia 1992; 33: 1083–90

    Article  PubMed  CAS  Google Scholar 

  22. Sugimoto T, Araki A, Yasuhara A, et al. Angelman syndrome in three siblings: genetic model of epilepsy associated with chromosomal DNA deletion of the GABA-A receptor. Jpn J Psychiatry Neurol 1994; 48: 271–3

    PubMed  CAS  Google Scholar 

  23. Guerrini R, De Lorey TM, Bonanni P, et al. Cortical myoclonus in Angelman syndrome. Ann Neurol 1996; 40: 39–48

    Article  PubMed  CAS  Google Scholar 

  24. Dalla Bernardina B, Zullini E, Fontana E, et al. Sindrome di Angelman: studio EEG-poligrafico di 8 casi. Boll Lega It Epil 1992; 79/80: 257–9

    Google Scholar 

  25. Minassian BA, DeLorey TM, Olsen RW, et al. Angelman syndrome: correlations between epilepsy phenotypes and genotypes. Ann Neurol 1998; 43: 485–93

    Article  PubMed  CAS  Google Scholar 

  26. Buntinx IM, Hennekam RCM, Brouwer OF, et al. Clinical profile of Angelman syndrome at different ages. Am J Med Genet 1995; 56: 176–83

    Article  PubMed  CAS  Google Scholar 

  27. Clayton-Smith J. Clinical research on Angelman syndrome in the United Kingdom: observations on 82 affected individuals. Am J Med Genet 1993; 46: 12–5

    Article  PubMed  CAS  Google Scholar 

  28. Penner KA, Johnston J, Faircloth BH, et al. Communication, cognition, and social interaction in the Angelman syndrome. Am J Med Genet 1993; 46: 34–9

    Article  PubMed  CAS  Google Scholar 

  29. Laan LAEM, den Boer AT, Hennekam RCM, et al. Angelman syndrome in adulthood. Am J Med Genet 1996; 66: 356–60

    Article  PubMed  CAS  Google Scholar 

  30. Williams CA, Lossie AC, Driscoll DJ. Angelman syndrome: GeneReviews [online]. Available from URL: http://www.geneclinics.org/profiles/angelman/ [Accessed 2003 Apr 9]

  31. Bottani A, Robinson WP, DeLozier-Blanchet CD, et al. Angelman syndrome due to paternal uniparental disomy of chromosome 15: a milder phenotype? Am J Med Genet 1994; 51: 35–40

    Article  PubMed  CAS  Google Scholar 

  32. Summers JA, Allison DB, Lynch PS, et al. Behaviour problems in Angelman syndrome. J Intellect Disabil Res 1995; 39: 97–106

    Article  PubMed  Google Scholar 

  33. Clarke DJ, Marston G. Problem behaviours associated with 15q-Angelman syndrome. Am J Ment Retard 2000; 105: 25–31

    Article  PubMed  CAS  Google Scholar 

  34. Clayton-Smith J. Angelman syndrome: evolution of the phenotype in adolescents and adults. Dev Med Child Neurol 2001; 43: 476–80

    Article  Google Scholar 

  35. Summers JA, Lynch PS, Harris JC, et al. A combined behavioral/pharmacological treatment of sleep-wake schedule disorder in Angelman syndrome. J Dev Behav Pediatr 1992; 13: 284–7

    Article  PubMed  CAS  Google Scholar 

  36. Sandanam T, Beange H, Robson L, et al. Manifestations in institutionalised adults with Angelman syndrome due to deletion. Am J Med Genet 1997; 70: 415–20

    Article  PubMed  CAS  Google Scholar 

  37. Buckley RH, Dinno N, Weber P. Angelman syndrome: are the estimates too low? Am J Med Genet 1998; 80: 385–90

    Article  PubMed  CAS  Google Scholar 

  38. Smith A, Marks R, Haan E, et al. Clinical features in four patients with Angelman syndrome resulting from paternal uniparental disomy. J Med Genet 1997; 34: 426–9

    Article  PubMed  CAS  Google Scholar 

  39. Lossie AC, Whitney M, Amidon D, et al. Genotype/phenotype correlations among the 5 molecular classes of Angelman syndrome [abstract]. Am J Hum Genet 2000; 67: 351

    Google Scholar 

  40. Fridman C, Varela MC, Kok F, et al. Paternal UPD15: further genetic and clinical studies in four Angelman syndrome patients. Am J Med Genet 2000; 92: 322–7

    Article  PubMed  CAS  Google Scholar 

  41. Gillessen-Kaesbach G, Demuth S, Thiele H, et al. A previously unrecognised phenotype characterised by obesity, muscular hypotonia, and ability to speak in patients with Angelman syndrome caused by an imprinting defect. Eur J Hum Genet 1999; 7: 638–44

    Article  PubMed  CAS  Google Scholar 

  42. King RA, Wiesner GL, Townsend D, et al. Hypopigmentation in Angelman syndrome. Am J Med Genet 1993; 46: 40–4

    Article  PubMed  CAS  Google Scholar 

  43. Stalker HJ, Williams CA. Genetic counseling in Angelman syndrome: the challenges of multiple causes. Am J Med Genet 1998; 77: 54–9

    Article  PubMed  CAS  Google Scholar 

  44. Butler MG. High resolution chromosome analysis and fluorescence in situ hybridization in patients referred for Prader-Willi or Angelman syndrome. Am J Med Genet 1995; 56: 420–2

    Article  PubMed  CAS  Google Scholar 

  45. Webb T. Inv dup(15) supernumerary marker chromosomes. J Med Genet 1994; 31: 585–94

    Article  PubMed  CAS  Google Scholar 

  46. Kubota T, Das S, Christian SL, et al. Methylation-specific PCR simplifies imprinting analysis. Nat Genet 1997; 16: 16–7

    PubMed  CAS  Google Scholar 

  47. Kubota T, Sutcliffe JS, Aradhya S, et al. Validation studies of SNRPN methylation as a diagnostic test for Prader-Willi syndrome. Am J Med Genet 1996; 66: 77–80

    Article  PubMed  CAS  Google Scholar 

  48. Kokkonen H, Leisti J. An unexpected recurrence of Angelman syndrome suggestive of maternal germ-line mosaicism of del(15)(q11q13) in a Finnish family. Hum Genet 2000; 107: 83–5

    Article  PubMed  CAS  Google Scholar 

  49. Stalker HJ, Williams CA, Wagstaff J. Genetic counseling in Angelman syndrome: gonadal mosaicism [letter]. Am J Med Genet 1998; 78: 482

    Article  PubMed  CAS  Google Scholar 

  50. Leonard CM, Williams CA, Nicholls RD, et al. Angelman and Prader-Willi syndrome: a magnetic resonance imaging study of differences in cerebral structure. Am J Med Genet 1993; 46: 26–33

    Article  PubMed  CAS  Google Scholar 

  51. Jay V, Becker LE, Chan FW, et al. Puppet-like syndrome of Angelman: a pathologic and neurochemical study. Neurology 1991; 41: 416–22

    Article  PubMed  CAS  Google Scholar 

  52. Kyriakides T, Hallam LA, Hockey A, et al. Angelman’s syndrome: a neuropatho-logical study. Acta Neuropathol 1992; 83: 675–8

    Article  PubMed  CAS  Google Scholar 

  53. Laan LAEM, Renier WO, Arts WFM, et al. Evolution of epilepsy and EEG findings in Angelman syndrome. Epilepsia 1997; 38: 195–9

    Article  PubMed  CAS  Google Scholar 

  54. Boyd SG, Harden A, Patton MA. The EEG in early diagnosis of the Angelman (happy puppet) syndrome. Eur J Pediatr 1988; 147: 508–13

    Article  PubMed  CAS  Google Scholar 

  55. Williams CA, Zori RT, Hendrickson J, et al. Angelman syndrome. Curr Probl Pediatr 1995; 25: 216–31

    Article  PubMed  CAS  Google Scholar 

  56. Lossie AC, Driscoll DJ. Transmission of Angelman syndrome by an affected mother. Genet Med 1999; 1: 262–6

    Article  PubMed  CAS  Google Scholar 

  57. Williams CA, Lossie A, Driscoll DRC. Angelman syndrome: mimicking conditions and phenotypes. Am J Med Genet 2001; 101: 59–64

    Article  PubMed  CAS  Google Scholar 

  58. Scheffer I, Brett EM, Wilson J, et al. Angelman’s syndrome [letter]. J Med Genet 1990; 27: 275–7

    Article  PubMed  CAS  Google Scholar 

  59. Nakatsu Y, Tyndale RF, DeLorey TM, et al. A cluster of three GABA-A receptor subunit genes is deleted in a neurological mutant of the mouse p locus. Nature 1993; 364: 448–50

    Article  PubMed  CAS  Google Scholar 

  60. Franz DN, Glauser TA, Tudor C, et al. Topiramate therapy of epilepsy associated with Angelman’s syndrome. Neurology 2000; 54: 1185–8

    Article  PubMed  CAS  Google Scholar 

  61. Sugiura C, Ogura K, Ueno M, et al. High-dose ethosuximide for epilepsy in Angelman syndrome: implication of GABA(A) receptor subunit. Neurology 2001; 57: 1518–9

    Article  PubMed  CAS  Google Scholar 

  62. Østergaard JR, Balslev T. Efficacy of different antiepileptic drugs in children with Angelman syndrome associated with 15q11-13 deletion: the Danish experience [letter]. Dev Med Child Neurol 2001; 43: 718–9

    Article  PubMed  Google Scholar 

  63. Kuenzle CH, Steinlin M, Wohlrab G, et al. Adverse effects of vigabatrin in Angelman syndrome. Epilepsia 1998; 39: 1213–5

    Article  PubMed  CAS  Google Scholar 

  64. Guerrini R, Dravet C, Genton P, et al. Lamotrigine and seizure aggravation in severe myoclonic epilepsy. Epilepsia 1998; 39: 508–12

    Article  PubMed  CAS  Google Scholar 

  65. Ruggieri M, McShane MA. Parental view of epilepsy in Angelman syndrome: a questionnaire study. Arch Dis Child 1998; 79: 423–6

    Article  PubMed  CAS  Google Scholar 

  66. Genton P, Gélisse P. Antimyoclonic effect of levetiracetam. Epileptic Disord 2000; 2: 209–12

    PubMed  CAS  Google Scholar 

  67. Zhdanova IV, Wurtman RJ, Wagstaff J. Effects of a low dose of melatonin on sleep in children with Angelman syndrome. J Pediatr Endocrinol Metab 1999; 12: 57–67

    Article  PubMed  CAS  Google Scholar 

  68. Saitoh S, Harada N, Jinno Y, et al. Molecular and clinical study of 61 Angelman syndrome patients. Am J Med Genet 1994; 52: 158–63

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

We wish to thank parents and children in the ORSA (Organizzazione sindrome di Angelman) for their commitment to the Italian Angelman syndrome network, and Professor O. Zuffardi for performing FISH studies in some of our patients.

The authors have no conflicts of interest directly relevant to the content of this review. The authors have provided no information on sources of funding directly relevant to the content of this review.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Renzo Guerrini.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Guerrini, R., Carrozzo, R., Rinaldi, R. et al. Angelman Syndrome. Pediatr-Drugs 5, 647–661 (2003). https://doi.org/10.2165/00148581-200305100-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00148581-200305100-00001

Keywords

Navigation